JP2022542524A - 抗ｃｃｒ５受容体薬剤の投与を含むがんを処置または予防する方法 - Google Patents

抗ｃｃｒ５受容体薬剤の投与を含むがんを処置または予防する方法 Download PDF

Info

Publication number
JP2022542524A
JP2022542524A JP2022506809A JP2022506809A JP2022542524A JP 2022542524 A JP2022542524 A JP 2022542524A JP 2022506809 A JP2022506809 A JP 2022506809A JP 2022506809 A JP2022506809 A JP 2022506809A JP 2022542524 A JP2022542524 A JP 2022542524A
Authority
JP
Japan
Prior art keywords
antibody
leronlimab
ccr5
binding fragment
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022506809A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022542524A5 (https=
Inventor
バーガー，デニス
ケリー，スコット
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cytodyn Inc
Original Assignee
Cytodyn Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytodyn Inc filed Critical Cytodyn Inc
Publication of JP2022542524A publication Critical patent/JP2022542524A/ja
Publication of JP2022542524A5 publication Critical patent/JP2022542524A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
JP2022506809A 2019-08-02 2020-07-31 抗ｃｃｒ５受容体薬剤の投与を含むがんを処置または予防する方法 Pending JP2022542524A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962882353P 2019-08-02 2019-08-02
US62/882,353 2019-08-02
US202063047693P 2020-07-02 2020-07-02
US63/047,693 2020-07-02
PCT/US2020/044616 WO2021026028A1 (en) 2019-08-02 2020-07-31 Methods for treating or preventing cancers involving the administration of anti-ccr5 receptor agents

Publications (2)

Publication Number Publication Date
JP2022542524A true JP2022542524A (ja) 2022-10-04
JP2022542524A5 JP2022542524A5 (https=) 2023-08-29

Family

ID=72193578

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022506809A Pending JP2022542524A (ja) 2019-08-02 2020-07-31 抗ｃｃｒ５受容体薬剤の投与を含むがんを処置または予防する方法

Country Status (9)

Country Link
US (1) US20220298249A1 (https=)
EP (1) EP4007603A1 (https=)
JP (1) JP2022542524A (https=)
CN (1) CN114502594A (https=)
AU (1) AU2020324948A1 (https=)
BR (1) BR112022001037A2 (https=)
CA (1) CA3146474A1 (https=)
MX (1) MX2022001411A (https=)
WO (1) WO2021026028A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023532019A (ja) * 2020-06-23 2023-07-26 マドン アドバイザーズ エルエルシー 抗ｃｃｒ５モノクローナル抗体ベースの組成物および方法
WO2025250666A1 (en) * 2024-05-29 2025-12-04 Cytodyn, Inc. Methods of treating cancer and inflammation-related diseases with leronlimab

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007332141A (ja) * 2006-06-12 2007-12-27 Pfizer Prod Inc 薬
WO2018209301A1 (en) * 2017-05-11 2018-11-15 Cytodyn Inc. Methods for treating or preventing graft-versus-host disease involving the administration of anti-ccr5 receptor agents

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6117679A (en) 1994-02-17 2000-09-12 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6165793A (en) 1996-03-25 2000-12-26 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6458355B1 (en) 1998-01-22 2002-10-01 Genentech, Inc. Methods of treating inflammatory disease with anti-IL-8 antibody fragment-polymer conjugates
US6365408B1 (en) 1998-06-19 2002-04-02 Maxygen, Inc. Methods of evolving a polynucleotides by mutagenesis and recombination
US7122185B2 (en) 2002-02-22 2006-10-17 Progenics Pharmaceuticals, Inc. Anti-CCR5 antibody
CA2616189C (en) 2005-07-22 2019-03-26 Progenics Pharmaceuticals, Inc. Methods for reducing viral load in hiv-1-infected patients
CA2939464A1 (en) * 2014-02-18 2015-08-27 Cytodyn Inc. Use of anti-ccr5 antibodies in graft versus host disease
CN107847514A (zh) 2015-06-23 2018-03-27 西托戴恩股份有限公司 炎症、癌症、自身免疫和其它病症中ccl5配体结合ccr5受体的抑制作用和ccr5/ccl5轴信号传导的改变

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007332141A (ja) * 2006-06-12 2007-12-27 Pfizer Prod Inc 薬
WO2018209301A1 (en) * 2017-05-11 2018-11-15 Cytodyn Inc. Methods for treating or preventing graft-versus-host disease involving the administration of anti-ccr5 receptor agents

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CANCER CELL, vol. 29, JPN6024026090, 2016, pages 587 - 601, ISSN: 0005519675 *
CANCER RES., vol. 72(15), JPN6024026094, 2012, pages 3839 - 3850, ISSN: 0005519678 *
CANCER RES., vol. 79(13_Supplement), JPN6024026092, 1 July 2019 (2019-07-01), pages 2009, ISSN: 0005519676 *
HIGHLEYMAN L., DISABLING CCR5 COULD BE KEY TO A CURE - BUT AT WHAT COST?[ONLINE](RETRIEVED ON 2024 JUN 26), JPN6024026093, 20 June 2019 (2019-06-20), ISSN: 0005519677 *

Also Published As

Publication number Publication date
BR112022001037A2 (pt) 2022-06-07
EP4007603A1 (en) 2022-06-08
WO2021026028A1 (en) 2021-02-11
CA3146474A1 (en) 2021-02-11
AU2020324948A1 (en) 2022-02-17
MX2022001411A (es) 2022-03-25
CN114502594A (zh) 2022-05-13
US20220298249A1 (en) 2022-09-22

Similar Documents

Publication Publication Date Title
JP6649254B2 (ja) ＩＬ−１５及びＩＬ−１５Ｒαスシドメインに基づくモジュロカイン
US20080107595A1 (en) Anti-CCR5 antibody
RU2322454C2 (ru) Антитело против ccr5
Markatseli et al. Certolizumab for rheumatoid arthritis
JP2022542524A (ja) 抗ｃｃｒ５受容体薬剤の投与を含むがんを処置または予防する方法
US20190016810A1 (en) Methods for treating or preventing graft-versus-host disease involving the administration of anti-ccr5 receptor agents
US20240270840A1 (en) Antibodies against cd112r and uses thereof
JP7583736B2 (ja) 癌転移をブロックまたはｄｎａ損傷化学療法によって誘導される細胞死を増強する抗ｃｃｒ５薬剤および処置の方法
US20240368288A1 (en) Bispecific anti-flt3/cd3 antibodies and methods of use
KR20220127859A (ko) Ccr5 양성 전이성 암 치료를 위한 ccr5 결합제
KR20230098201A (ko) 줄기 세포 동원의 유도 방법
US20250179204A1 (en) Anti glucocorticoid-induced tnfr-related (gitr) protein antibodies and uses thereof
JP2025540215A (ja) Ｃｄ４７遮断剤と抗ｂｃｍａ／抗ｃｄ３二重特異性抗体との組合せ療法
JP2025523501A (ja) Ｎａｆｌｄおよびｎａｓｈを処置する方法
WO2025106552A1 (en) Methods and compositions for treatment of leukemia
JP2025084100A (ja) 抗ｔｎｆｒ２抗体およびその使用の方法
JP2025517490A (ja) 抗ｔｎｆｒ２抗体およびその使用の方法
HK1131343A (en) Anti-ccr5 antibody
HK1072272B (en) Anti-ccr5 antibody

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220512

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230731

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230731

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230821

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240703

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241003

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250106

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250204